Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Neflamapimod
Cat. No.:
0225LY-0505
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Neflamapimod inhibits p38α with high potency (IC50 = 10 nM) and shows 22-fold higher specificity for the α isoform over p38β, while remaining inactive against p38γ.
Synonym:
VX-745; 209410-46-8; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 6H-Pyrimido[1,6-b]pyridazin-6-one, 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]-
CAS No.:
209410-46-8
Compound CID:
3038525
Formula:
C19H9Cl2F2N3OS
Formula Weight:
436.26
Specification
Targets&IC50:
p38α: 10 nM; p38β: 220 nM
Relative Density:
1.55 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Neflamapimod can be used in neurological research to evaluate its potential in reversing synaptic dysfunction in Alzheimer’s disease.
Library Information
Target:
p38 MAPK
Receptor:
p38α; p38β
Pathways:
Autophagy; MAPK
Plate Number:
AOCL-7
Plate Location:
e7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
16.7 mg/mL; 38.28 mM
ALogP:
5.342
HBA_Count:
3
HBD_Count:
0
Rotatable Bond:
3
